By Alicia Wallace
A federal appeals court this week dealt a blow to makers of CBD-rich cannabis extracts who were trying to stop the Drug Enforcement Administration from considering their products as dangerous drugs.
A panel of judges for the 9th U.S. Circuit Court of Appeals shot down the hemp industry’s challenge of a DEA rule that established a drug code for marijuana extracts.
DEA officials had said the code was intended to track cannabis derivatives used in research and to meet treaty obligations, adding that these extracts and byproducts remain Schedule I substances that the government says have no accepted medical use, such as heroin, LSD, peyote and ecstasy.
Read more at The Denver Post